The TIF Procedure: Addressing the GERD Treatment Gap
Raman Muthusamy, MD, MAS Professor of Medicine Medical Director of Endoscopy UCLA Health ...
Read MoreDec 6, 2021
Raman Muthusamy, MD, MAS Professor of Medicine Medical Director of Endoscopy UCLA Health ...
Read MoreDec 3, 2021
Individuals with bipolar disorder (BD) or posttraumatic stress disorder (PTSD) often present for treatment in primary care settings, particularly in safety net primary care clinics where there is a high prevalence of both...
Read MoreNov 30, 2021
Patients with gout have significantly greater intercritical inflammation and lumbosacral spine monosodium urate crystal (MSU) deposition when compared with those without the condition, and trend toward greater deposition among...
Read MoreNov 30, 2021
Pegloticase is effective for lowering serum urate patients with uncontrolled or refractory gout, although more than half of patients experience anti-drug antibody development which limits its efficacy.1 Administering pegloticase...
Read MoreNov 29, 2021
The American Society of Hematology Annual Meeting & Exposition (ASH 2021) Will be held December 11-14, 2021 at the Georgia World Congress Center in Atlanta, as well as virtually. The “premier event in malignant and...
Read MoreNov 29, 2021
(WASHINGTON, Nov. 22, 2021) – The American Society of Hematology (ASH) will honor Representative Rosa DeLauro (D-CT) for her outstanding support of hematology research at the 2021 ASH Annual Meeting, December 11-14, in Atlanta,...
Read MoreNov 29, 2021
(WASHINGTON, Nov. 22, 2021) – The American Society of Hematology (ASH) will honor Peter Marks, MD, PhD, Director of the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA) for his...
Read MoreNov 29, 2021
MIRROR RCT (NCT03994731) phase III data support the combination of immunosuppression with pegloticase treatment for uncontrolled gout in all patients, raising the response rate from 40-42% to 71%. Physician’s Weekly spoke with...
Read MoreNov 23, 2021
In the phase IV open-label PROTECT trial of pegloticase therapy (pegylated recombinant uricase) in treating severe gout in renal transplant recipients, 89% of patients achieved the primary endpoint of serum uric acid (sUA) less...
Read MoreNov 23, 2021
As apps play an expanding role in mental healthcare, their complexity is, in some cases, simultaneously increasing, explains Adam C. Powell, PhD. “Understanding the value delivered by apps, and how to quantify it, is an...
Read MoreNov 23, 2021
We recently spoke with Andrea Lora Kossler, MD, FACS, from the Byers Eye Institute at Stanford University about results from the study “Effect of Teprotumumab on Ocular Surface Disease in Active Thyroid Eye Disease,” which she...
Read MoreNov 22, 2021
A post-hoc analysis of data from the ORION-9, ORION-10, and ORION-11 trials, presented during the...
Read MoreNov 22, 2021
According to a biomarker sub-study of patients with heart failure with reduced ejection fraction...
Read MoreNov 22, 2021
Current treatments for T1D place a heavy burden on patients. Every day, they must measure their...
Read MoreNov 19, 2021
Physician’s Weekly spoke recently with Roman Shinder, MD, FACS, from the Departments of Ophthalmology and Otolaryngology at SUNY Downstate Medical Center, about study results he and his colleague, Anna Artymowicz, MD, presented...
Read MoreNov 18, 2021
Looking back at a year and a half of significant changes to our way of life, it is easy to become...
Read MoreNov 17, 2021
Despite being below the middle earners for more than 29 physician specialties surveyed in the past several years, nephrologists are among the few medical specialists to see a notable increase in earnings year-over-year,...
Read MoreNov 17, 2021
Data show that transoral incisionless fundoplication (TIF) may be an effective endoscopic...
Read MoreNov 17, 2021
As endoscopic management of GERD increases, researchers aimed to examine the available evidence on...
Read More